Coated (e.g., Microcapsules) Patents (Class 424/490)
  • Patent number: 11401485
    Abstract: A microcapsule system having an outer microcapsule with an outer capsule shell is disclosed. The outer microcapsule comprises at least one inner microcapsule with an inner capsule shell and a first fragrance composition. The inner microcapsule comprises a second fragrance composition that differs from the first fragrance composition. Methods for the production of such micr, products that contain said microcapsules, methods for producing polysensory olfactory impressions and to the corresponding use of the microcapsule system.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: August 2, 2022
    Assignee: Henkel AG & Co. KGaA
    Inventors: Andreas Bauer, Andre Haetzelt, Frank Pessel, Andreas Gerigk, Anneliese Wilsch-Irrgang, Klaus Last, Raul Amado Muñoz
  • Patent number: 11401479
    Abstract: The invention relates to a sliding member having a first sliding surface, wherein the first sliding surface (29) comprises a particulate support material (6) and a graphene-containing material (7), wherein the particulate support material (6) is at least partially coated with the graphene-containing material (7), and wherein a material bond (14) is present between the particulate support material (6) and the graphene-containing material (7).
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: August 2, 2022
    Assignee: EagleBurgmann Germany GmbH & Co. KG
    Inventors: Rolf Mulhaupt, Jorg Thomas Thelke, Wenli Zhang
  • Patent number: 11389408
    Abstract: The present invention relates to a method for preparing a protocell in form of a giant unilamellar vesicle, which comprises the following steps: a) providing a water-based droplet encapsulated by an outer polymer shell, which borders the inner space of the droplet, wherein the droplet has a maximum dimension of 0.5 ?m to 1,000 ?m, wherein the inner space of the droplet contains at least one lipid, b) transforming the lipid content of the droplet into a lipid bilayer which is arranged at and covers the inner surface of the polymer shell and oil phase in order to form a polymer shell-stabilized giant unilamellar vesicle, c) optionally incorporating one or more proteins and/or nuclei into the polymer shell-stabilized giant unilamellar vesicle provided in step b) and d) optionally removing the polymer shell and oil phase from the polymer shell-stabilized giant unilamellar vesicle and optionally transferring it from the oil to the water phase.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: July 19, 2022
    Inventors: Joachim P. Spatz, Lucia T. Benk, Johannes Patrick Frohnmayer, Barbara Haller, Jan-Willi Janiesch, Yilia Plazman, Marian Weiss
  • Patent number: 11387013
    Abstract: A deformable yet mechanically resilient microcapsule having electrical properties, a method of making the microcapsules, and a circuit component including the microcapsules. The microcapsule containing a gallium liquid metal alloy core having from about 60 to about 100 wt. % gallium and at least one alloying metal, and a polymeric shell encapsulating the liquid core, said polymeric shell having conductive properties.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: July 12, 2022
    Assignee: United States of America as represented by the Secretary of the Air Force
    Inventors: Brad L Cumby, Christopher Tabor
  • Patent number: 11357733
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: June 14, 2022
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 11318470
    Abstract: Microfluidic devices and nanobiosensors comprising a magnetic nanoparticle attached to a reporter molecule via a release unit for microfluidic-based detection of a target analyte in a biological sample. The nanobiosensors can be magnetically manipulated or guided through the microfluidics channels for incubation with the biological sample, concentration of the nanobiosensors, and detection of target analytes, without having to pump the entire initial sample through a microfluidic channel of the microfluidic device. The magnetic nanoparticles are separated from the reporter molecules before detection and can be re-used.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 3, 2022
    Assignee: Kansas State University Research Foundation
    Inventors: Christopher T. Culbertson, Stefan H. Bossmann
  • Patent number: 11309382
    Abstract: An electronic product that includes a component having a first electrode with a first surface and a pillar extending from the first surface in a first direction, the pillar having three protrusions, the three protrusions forming angles of about 120 degrees with each other around a central line of the pillar where the three protrusions meet, and the three protrusions being bent so that the pillar has a triskelion cross-section in a plane perpendicular to the first direction.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: April 19, 2022
    Assignee: MURATA MANUFACTURING CO., LTD.
    Inventors: Stéphane Bouvier, Florent Lallemand
  • Patent number: 11272858
    Abstract: A capsule device configured to navigate through a patient's GI track is disclosed. System and method to turn on the capsule device based on acceleration is described. First the capsule is monitored at a slow sampling mode. Then the capsule is monitored at a fast sampling mode. A user can input hand motion to change the acceleration to turn on the capsule device.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: March 15, 2022
    Assignee: ANKON MEDICAL TECHNOLOGIES (SHANGHAI) CO., LTD.
    Inventor: Xiaodong Duan
  • Patent number: 11241391
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: February 8, 2022
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 11241392
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: February 8, 2022
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 11235019
    Abstract: Some embodiments comprise dietary supplements for treating or preventing traveler's diarrhea comprising: (a) about 1000 mg green tea extract comprising at least 90% (w/w) catechins; (b) about 4 g partially hydrolyzed guar gum (PHGG); (c) about 100 mg L-theanine; and (d) about 5 g non-sugar sweetener, wherein the sweetener does not contain a polyol. Some embodiments comprise dietary supplement for treating or preventing traveler's diarrhea comprising: (a) from about 250 mg to about 1,500 mg green tea extract comprising at least 90% (w/w) catechins; (b) from about 1 g to about 8 g partially hydrolyzed guar gum (PHGG); and (c) from about 15 mg to about 250 mg L-theanine.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 1, 2022
    Assignee: ARTESA LLC
    Inventor: William E. Driessen
  • Patent number: 11224657
    Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Société des Produits Nestlé S. A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 11224760
    Abstract: Semisolid oral dispersions for whitening teeth. The semisolid oral dispersions include hydrophilic bleaching agent particles in a hydrophobic phase. The hydrophilic bleaching agent particles can include peroxide compounds and/or hydrogen peroxide adducts. The hydrophilic bleaching agent particle can have a solubility in water of at least about 20 parts, by weight of the particles, in about 100 parts, by weight, of water.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: January 18, 2022
    Assignee: The Procter & Gamble Company
    Inventors: Paul Albert Sagel, Jayanth Rajaiah, Michael David Curtis
  • Patent number: 11207423
    Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: December 28, 2021
    Assignee: Northwestern University
    Inventors: Jack Henkin, Ignacio Melgar-Asensio
  • Patent number: 11202463
    Abstract: Provided herein are formulations of flavors and fragrances encapsulated in plasmolysed micro-organisms, as well as glass particles or beads comprising these encapsulated flavors and fragrances. Also provided herein are methods of making formulations of encapsulated flavors and fragrances.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: December 21, 2021
    Assignee: FIRMENICH SA
    Inventors: Pierre-Etienne Bouquerand, Nathalie Vivien Castioni, Anupama Koorapati, Serge Maio, François Meyer
  • Patent number: 11197842
    Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 14, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi
  • Patent number: 11177078
    Abstract: A precursor for a light absorbing layer, including a perovskite precursor, and a fluorine-based organic compound in an amount of 0.005 wt % to 0.5 wt % based on the mass of the perovskite precursor, and a method for manufacturing an organic-inorganic hybrid solar cell using the same.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: November 16, 2021
    Assignee: LG CHEM, LTD.
    Inventors: Yongnam Kim, Yun Hye Hahm, Jong Seok Kim, Sang Jun Park, Seiyong Kim
  • Patent number: 11169147
    Abstract: This invention relates to a method of immobilizing a protein on particles, and more particularly to a method of immobilizing an antibody on magnetic particles. The method of immobilizing the protein on the particles can prevent aggregation due to non-specific binding between proteins and between proteins and particles, whereby a relatively small amount of protein can be immobilized on particles.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: November 9, 2021
    Assignee: AMOLIFESCIENCE CO., LTD.
    Inventors: Sung-Il Kim, Seam Mun
  • Patent number: 11167031
    Abstract: Provided is a novel additive for an orally disintegrating tablet providing quick disintegrability and tablet hardness to the orally disintegrating tablet, and a producing method therefor. According to an embodiment of the present invention, there is provided an additive for an orally disintegrating tablet characterized by including D-mannitol, low-substituted hydroxypropyl cellulose (however, excluding the low-substituted hydroxypropyl cellulose having a mean particle size of 20 ?m or less and a substitution degree of hydroxypropoxy groups of 11%, a mean particle size of 45 ?m or less and a substitution degree of hydroxypropoxy groups of 14%, and a mean particle size of 45 ?m or less and a substitution degree of hydroxypropoxy groups of 11% and a 90% cumulated particle size of 100 ?m or less), crospovidone, and microcrystalline cellulose, wherein the low-substituted hydroxypropyl cellulose and the crospovidone are included in a ratio of 5:4.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: November 9, 2021
    Assignee: SAWAI PHARMACEUTICAL Co., Ltd.
    Inventors: Yoichi Higashiyama, Wataru Izui, Ayako Harada, Satoru Ogihara, Kenji Nozawa, Hiroaki Kikuoka
  • Patent number: 11161747
    Abstract: Described are composite photonic materials that incorporate magnetic nanoparticles inside hollow or solvent-filled nano-scale or micro-scale shells and methods of making and using such composite photonic materials. When these photonic materials are present in a magnetic field, they exhibit a change in reflected, scattered, and/or transmitted light as compared to when the materials are not in the presence of the magnetic field. This results in the materials appearing to have a different color, such as when observed by the human eye or a light detecting device, such as a camera.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: November 2, 2021
    Assignee: The Regents of the University of California
    Inventor: Ting Guo
  • Patent number: 11123322
    Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: September 21, 2021
    Assignee: Crititech, Inc.
    Inventors: Michael Baltezor, Joseph Farthing, Jake Sittenauer, Jahna Espinosa, Samuel Campbell, Matthew McClorey, Julia K. Fischer, Mark D. Williams, Gary E. Clapp
  • Patent number: 11116793
    Abstract: A modified metal nanoparticle comprising a metal nanoparticle and a cyclic polyether modifying the metal nanoparticle.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: September 14, 2021
    Assignee: National University Corporation Hokkaido University
    Inventors: Takuya Yamamoto, Jose Enrico Quinsaat
  • Patent number: 11116725
    Abstract: The subject invention pertains to polyacrylate homopolymers produced from acrylolated drug monomers. The homopolymers can be produced in the form of nanoparticles. The nanoparticles comprising the homopolymers can be produced via a free radical-induced emulsion polymerization of the acrylolated drug monomers to produce an aqueous emulsion of uniformly sized nanoparticles. The homopolymers of the invention containing acrylolated antibiotic monomers can be active against Gram-positive and Gram-negative bacteria, such as Staphylococcus aureus and Escherichia coil. Accordingly, methods are provided of treating a disease, for example, an infection, by administering to a subject the homopolymers, homopolymeric nanoparticles, or emulsions containing homopolymeric nanoparticles of the invention.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: September 14, 2021
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Edward Turos, Faeez Mahzamani
  • Patent number: 11096391
    Abstract: The present disclosure is directed to a sanitizing composition for dispensing into aquatic systems. The sanitizing composition contains a sanitizing agent containing water molecules that have been bound within the composition by a water binder. In one embodiment, the sanitizing agent is a polybiguanide salt and the water binder is an anhydrous salt. The resulting composition can be a solid that can be packaged in water degradable or water soluble packages for ease of handling and dispensing.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: August 24, 2021
    Assignee: INNOVATIVE WATER CARE, LLC
    Inventors: Volodymyr B. Pashovych, Matthew Muller, Shannon Lafferty, Karen L. Boyd
  • Patent number: 11090626
    Abstract: The present invention provides a process for producing nanoparticles, comprising: providing a first liquid comprising a metal salt and at least one species of ligand having a functional group capable of binding to a metal surface, providing a second liquid comprising a reducing agent; providing at least one liquid droplet generator operable to generate liquid droplets, causing the at least one liquid droplet generator to form liquid droplets of the first liquid, passing the liquid droplets through a gas to contact the second liquid so as to cause the metal salt and the at least one species of ligand to come into contact with the reducing agent, thereby causing self-assembly of nanoparticles, said nanoparticles having a core of said metal and a corona comprising a plurality of said ligands covalently bound to the core. Also provided are nanoparticles produced by the process of the invention and use of such nanoparticles in medicine.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: August 17, 2021
    Inventors: Daniel Palmer, Rhian Groves, Paul Seaman, Victoria Cavalier-Hirth, Alessandro Pace
  • Patent number: 11077196
    Abstract: Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: August 3, 2021
    Assignee: G.L. PHARMA GMBH
    Inventors: Georg Guebitz, Katrin Greimel, Martin Brandauer, Daniela Huber, Klaus Bleymaier, Wolfgang Kroutil, Doris Lechner, Christof Wachter, Harald Wagner, Heimo Winkler
  • Patent number: 11077193
    Abstract: The present invention discloses nerve growth factor composition and an injection powder comprising the following components: 10 ?g/mL-100 ?g/mL of a nerve growth factor; 10 mg/mL-80 mg/mL of disaccharide stabilizer; 0 mg/mL-30 mg/mL of an amino acid stabilizer; 0.01 mg/mL-1 mg/mL of surfactant, 10 mg/mL-50 mg/mL of a supporting agent; a pH buffer for maintaining the nerve growth factor composition at 6.0-7.4, and solvent being water. The nerve growth factor composition and the injection powder can avoid the potential risk resulting from the virus of other unknown components carried in albumin by using a disaccharide or a combination of a disaccharide and an amino acid instead of albumin as a stabilizer; not only have protective effect on mNGF, but also can ensure the stability of hNGF and rhNGF in the preparation, transportation and storage processes, and have better medication safety and quality control.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 3, 2021
    Assignees: STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD., BEIJING STAIDSON MEDICAL. TECHNOLOGY CO.. LTD.
    Inventors: Jianping Tan, Bingzhang Wang
  • Patent number: 11060015
    Abstract: A treatment fluid comprises: a base fluid; a viscoelastic surfactant gelling agent and hydrophobic nanoparticles comprising metallic nanoparticles that are surface modified with C6-30 aliphatic groups. The treatment fluid is a fracturing fluid, a completion fluid, a gravel pack fluid, a fluid loss pill, a lost circulation pill, a diverter fluid, a foamed fluid, a stimulation fluid and the like.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: July 13, 2021
    Assignee: BAKER HUGHES, A GE COMPANY, LLC
    Inventors: Shiv Shankar Sangaru, Prahlad Yadav, Tianping Huang, Gaurav Agrawal, Pranjal Sarmah
  • Patent number: 11026892
    Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85% w/w API particles; 15-30% w/w coating material coating the API particles; and 3-15% w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60% relative humidity.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: June 8, 2021
    Assignee: Catalent U.K. Swindon Zydis Limited
    Inventors: Rosaleen McLaughlin, Simon Andrew Martyn Howes, Craig Wheadon, Jonathon Whitehouse
  • Patent number: 11026879
    Abstract: The invention deals with a dispersion of drops of a first phase in a second phase substantially immiscible with the first phase, the solubility of the first phase in the second phase being less than 5% by mass. Each drop includes a core formed with a first phase and a shell formed with a coacervate layer interposed between the first phase and the second phase. The coacervate layer comprises a first precursor polymer of the coacervate and a second precursor polymer of the coacervate, one of the first phase and of the second phase is aqueous, and the other of the first phase and of the second phase is oily.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: June 8, 2021
    Assignee: CAPSUM
    Inventors: Mathieu Goutayer, Jerome Bibette
  • Patent number: 11013693
    Abstract: The present invention relates to a process for the preparation of an oral pharmaceutical preparation in the form of enteric coated granulate comprising dimethyl fumarate and pharmaceutically acceptable excipients. The invention relates also to an oral pharmaceutical preparation in the form of enteric coated granulate obtained by the process of the present invention and to use of the preparation in the treatment of multiple sclerosis.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: May 25, 2021
    Inventors: Przemyslaw Skoczen, Aleksandra Drozd, Marek Cichocki
  • Patent number: 11013908
    Abstract: A nanodevice includes an array of metal nanorods formed on a substrate. An electropolymerized electrical conductor is formed over tops of a portion of the nanorods to form a reservoir between the electropolymerized conductor and the substrate. The electropolymerized conductor includes pores that open or close responsively to electrical signals applied to the nanorods. A cell loading region is disposed in proximity of the reservoir, and the cell loading region is configured to receive stem cells. A neurotrophic dispensing material is loaded in the reservoir to be dispersed in accordance with open pores to affect growth of the stem cells when in vivo.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: May 25, 2021
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Steven J. Holmes, Qinghuang Lin, Emily R. Kinser, Nathan P. Marchack, Roy R. Yu
  • Patent number: 10996496
    Abstract: In present invention, various embodiments provide a photothermotropic composite film. The composite film comprises a matrix and one or more nanostructures comprising a metal oxide semiconductor which is configured to convert radiant energy to thermal energy. The matrix has a property which is changeable based on the thermal energy received by the matrix from the metal oxide semiconductor. In a preferred embodiment, hybridization of the poly(N-isopropylacrylamide) (PNIPAM) hydrogel and antimony-tin oxide (ATO) is provided as the composite film. In this film, the ATO absorbs at near-infrared (NIR) region and acts as nanoheater to induce the optical switching of the hydrogel. The behaviour of this composite film can be used as a new generation of autonomous passive smart windows for climate-adaptable solar modulation.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 4, 2021
    Assignee: Nanyang Technological University
    Inventors: Xiao Hu, Heng Yeong Lee
  • Patent number: 10973925
    Abstract: Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 13, 2021
    Assignees: University of Central Florida Research Foundation Inc., Sanford Burnham Prebys Medical Discovery Institute at Lake Nona, Memorial Sloan Kettering Cancer Center
    Inventors: Annette Khaled, Jesus Manuel Perez Figueroa, Santimukul Santra, Charalambos Kaittanis, Oscar Santiesteban, Jan Grimm, Hampton Sessions
  • Patent number: 10967295
    Abstract: Methods for making high-purity LiFSI salts and intermediate products using one, the other, or both of a reactive-solvent removal/replacement method and an LiFSI purification method. In some embodiments, the reactive-solvent removal/replacement method includes using non-reactive anhydrous organic solvents to remove and/or replace one or more reactive solvents in a crude LiFSI. In some embodiments, the LiFSI purification method includes using anhydrous organic solvents to remove impurities, such as synthesis impurities, from a crude LiFSI. In some embodiments, crude LiFSI can be made using an aqueous-based neutralization process. LiFSI salts and products made using methods of the disclosure are also described, as are uses of such salts and products and electrochemical devices that include such salts and products.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: April 6, 2021
    Assignee: SES Holdings Pte. Ltd.
    Inventors: Rajendra P. Singh, Qichao Hu
  • Patent number: 10960000
    Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: March 30, 2021
    Assignee: RECRO GAINESVILLE LLC
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell
  • Patent number: 10953043
    Abstract: Stabilized multi-component antimicrobial compositions for treating tissue diseases, infections or conditions include a first and second set of differently sized and/or differently shaped metal nanoparticles, and a stabilizing agent. Compositions and treatment methods may be used for treating tissue diseases, infections or conditions caused by microbial infections, such as bacteria, viral, and/or fungal infections, or for preventing the infection of a wound, such as a cut, abrasion, ulcer, lesion, sore, and the like. The compositions and treatment methods disclosed herein may also be used as a prophylactic, and in some embodiments may be applied to otherwise healthy tissue in order to prevent or reduce the occurrence of a tissue disease, infection or condition.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: March 23, 2021
    Assignee: ATTOSTAT, INC.
    Inventors: Bryon J. Tarbet, William H. Niedermeyer
  • Patent number: 10940336
    Abstract: A method of encapsulation of an active comprising (a) dispersing an active in an aqueous medium having a pH of less than 6; (b) causing the formation on this dispersed active of a polymer shell, the formation comprising the sequential deposition of a series of polymeric layers, each layer being capable of hydrogen bonding with the preceding layer; to form an aqueous slurry of active-containing capsules; characterised in that one of the first two layers is a polycarboxylic acid and that the first two to four layers taken together exhibit an interfacial compression dilation modulus of greater than 10 mN/m. The method allows the precise tailoring of polymeric shells, allowing capsules walls to be much thinner without a loss of strength. The technique is especially useful for the encapsulation of fragrances and flavours.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: March 9, 2021
    Assignee: GIVAUDAN SA
    Inventors: Stephane Bone, Cédric Geffroy, Sandrine Le Tirilly, Patrick Perrin, Claire Vautrin, Cècile Monteux, Nadége Pantoustier
  • Patent number: 10940456
    Abstract: Hydrogenated amorphous silicon-containing colloids or composite colloids have a silicon-containing shell which surrounds the hollow colloids or composite colloids. The colloids have a spherical geometry. The silicon-containing composite colloids have a spherical geometry and a diameter of between 2 nm and 7 nm in scanning electron micrographs, and the silicon-containing colloids have a spherical geometry with a cavity and a diameter of between 50 and 200 nm in scanning transmission electron micrographs. The cavity is surrounded by a shell with a thickness of between 3 and 10 nm.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: March 9, 2021
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventors: Andrew Paolo Cadiz Bedini, Benjamin Klingebiel, Stefan Haas, Jan Flohre, Reinhard Carius, Chunguang Chen, Peter Notten
  • Patent number: 10933129
    Abstract: Disclosed are methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 2, 2021
    Assignee: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Conlin O'Neil, Petr Ilyinskii
  • Patent number: 10926079
    Abstract: A nanodevice includes an array of metal nanorods formed on a substrate. An electropolymerized electrical conductor is formed over tops of a portion of the nanorods to form a reservoir between the electropolymerized conductor and the substrate. The electropolymerized conductor includes pores that open or close responsively to electrical signals applied to the nanorods. A cell loading region is disposed in proximity of the reservoir, and the cell loading region is configured to receive stem cells. A neurotrophic dispensing material is loaded in the reservoir to be dispersed in accordance with open pores to affect growth of the stem cells when in vivo.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: February 23, 2021
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Steven J. Holmes, Qinghuang Lin, Emily R. Kinser, Nathan P. Marchack, Roy R. Yu
  • Patent number: 10918852
    Abstract: A nanodevice includes an array of metal nanorods formed on a substrate. An electropolymerized electrical conductor is formed over tops of a portion of the nanorods to form a reservoir between the electropolymerized conductor and the substrate. The electropolymerized conductor includes pores that open or close responsively to electrical signals applied to the nanorods. A cell loading region is disposed in proximity of the reservoir, and the cell loading region is configured to receive stem cells. A neurotrophic dispensing material is loaded in the reservoir to be dispersed in accordance with open pores to affect growth of the stem cells when in vivo.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: February 16, 2021
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Steven J. Holmes, Qinghuang Lin, Emily R. Kinser, Nathan P. Marchack, Roy R. Yu
  • Patent number: 10905652
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: February 2, 2021
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 10898442
    Abstract: The invention provides a gelated mono-nuclear microencapsulate comprising a lipid emulsion core encapsulated within a gastro-resistant, ileal sensitive, polymerized chitosan membrane shell, wherein the lipid emulsion core comprises denatured or hydrolysed protein and carbohydrate. In one embodiment of the invention, the emulsion is a micro-emulsion, and typically comprises a surfactant and a co-surfactant or at least two carbohydrates, for example sucrose and a maltodextrin. In one embodiment of the invention, the lipid is a marine derived lipid such as fish oil, krill oil, or nutraceutical fatty acids. In other embodiment, the lipid is a fatty acid such as DHA or ARA, or a lipid derived from seeds, nuts or eggs.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: January 26, 2021
    Assignee: Anabio Technologies Limited
    Inventor: Sinead Bleiel
  • Patent number: 10894085
    Abstract: The system comprises a support to receive a nanoparticle assembly (NPA) and to be conveyed towards a localized area of an organism infected or at risk to be infected by microorganisms; said nanoparticle assembly (NPA) comprising a plurality of nanoparticles (NPs) each one (NP) having a metal core and a surface surrounding said metal core, the metal core being reactable to thermal energy; and an energy unit (15) configured to apply at least one thermal shot on said localized area exposed to the nano-particle assembly, increasing the temperature of said localized area via the. nanoparticle assembly (NPA), so enabling a nanotheranostic multimodal antimicrobial therapy, wherein the metal core being made of silver, gold, iron or a mixture of silver and gold.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: January 19, 2021
    Assignees: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA, FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
    Inventors: Joan Gavalda Santapau, Victor Franco Puntes, Eduard Torrents Serra
  • Patent number: 10881618
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: January 5, 2021
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 10874622
    Abstract: Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the chitosan nanoparticles are coated with polylactic acid. Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease are also disclosed. For example, the treatment of ovarian cancer in a subject by inhibiting the expression of ZNF034 is disclosed.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 29, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Burcu Aslan, Gabriel Lopez-Berestein, Anil K. Sood
  • Patent number: 10869841
    Abstract: Methods, systems, and devices are disclosed for encapsulating biological entities with preservation of their biological activity. In one aspect, a method of encapsulating a biological entity includes templating a biocompatible material onto a biological structure to form a coating structure enclosing the biological structure, the coating structure having a size in the nanometer range, in which the coated biological structure preserves its biological activity within the coating structure. In some implementations of the method, the biological structure includes a virus and the biocompatible material includes silica.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: December 22, 2020
    Assignee: The Regents of the University of California
    Inventors: Inanc Ortac, Gen Yong, Michael Benchimol, Sadik C. Esener
  • Patent number: 10851547
    Abstract: Disclosed are methods to produce composite materials, which contain customized mixes of nano- and/or micro-particles with tailored electromagnetic spectral properties. In some defense-related applications, the use of such materials enables an improved spectral match between different structures, such as vehicles or buildings with the surrounding environment at least in the VIS and NIR wavelength range. This can camouflage the structures, and reduce the detectability thereof by ground-, air- or space-based multi-spectral long-range imaging systems, including aircrafts, drones, and satellites, and thus, generally delay, complicate, or eliminate detection or classification of the camouflaged structures.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 1, 2020
    Inventors: William Boone Daniels, II, Andreas Hieke
  • Patent number: 10850246
    Abstract: The invention provides a new method for preparing ultra-small polymeric-lipidic delivery nanoparticles (USDNs) that were synthesized by a nanoprecipitation method followed by a layer-by-layer nanodeposition. The USDNs particle size can be controlled between 5-25 nm and provides loading capacities of 22.12% to 72.08%. Moreover, the USDNs platform provides pH controlled drug release, within a terminal release ratio of 68% at pH 5.0 and almost no release to pH of 7.5. Furthermore, based on their small sizes (5-25 nm) and unique composition, the USDNs penetrates the skin strata efficiently, release the payload at the target site as topical or transdermal treatment of a variety of skin disorders. Additionally the USDNs system can be used to treat and diagnoses other crucial diseases (Cancer, Alzheimer, etc) can be combined with various micro-needles or needles free array technologies for special application.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: December 1, 2020
    Assignee: IndagoMed, LLC
    Inventor: Anamaria Orza